Ovid Therapeutics Inc. Ovid Therapeutics Inc.

Ovid Therapeutics Inc.

OVID

Rank in Stocks #12399
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating... Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Share Price
$2.20
Last synced: 2026-11-20
Market Cap
$446.65M
Change (1 day)
-5.98%
Change (1 year)
57.14%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Ovid Therapeutics Inc. (OVID)
EPS as of September 2026 TTM: $-0.41
According to Ovid Therapeutics Inc.'s latest financial reports, its current EPS (TTM) is $-0.41. At the end of 2025 the company had an EPS of $-0.24, an increase over its 2024 EPS of $-0.37.
EPS history for Ovid Therapeutics Inc. from 2014 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.41 70.83%
2025 $-0.24 -35.14%
2024 $-0.37 -50.00%
2023 $-0.74 -3.90%
2022 $-0.77 -143.26%
2021 $1.78 -228.06%
2020 $-1.39 -7.95%
2019 $-1.51 -28.44%
2018 $-2.11 -37.01%
2017 $-3.35 193.86%
2016 $-1.14 70.15%
2015 $-0.67 612.77%
2014 $-0.09 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$15.66 -3,919.51%
US
$-7.07 1,624.39%
US
$-5.29 1,190.24%
AU
$12.73 -3,205.41%
BE
$21.56 -5,358.54%
NL

Questions about Ovid Therapeutics Inc.'s earnings per share (EPS)

What is Ovid Therapeutics Inc.'s earnings per share (EPS)?

Ovid Therapeutics Inc.'s earnings per share (EPS) over the last twelve months is $-0.41, as of Sep 2026.

What was Ovid Therapeutics Inc.'s earnings per share (EPS) in 2025?

In 2025, Ovid Therapeutics Inc.'s earnings per share (EPS) was $-0.24, compared with $-0.37 in 2024.

How has Ovid Therapeutics Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Ovid Therapeutics Inc.'s earnings per share (EPS) was highest in 2021 ($1.78) and lowest in 2020 ($-1.39).

How does Ovid Therapeutics Inc.'s earnings per share (EPS) compare with similar companies?

Ovid Therapeutics Inc.'s earnings per share (EPS) ($-0.41) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.